What is the latest price of dabrafenib? 2025 Price Forecasts and Drug Pricing

Dabrafenib, as a targeted treatment drug for BRAF mutant tumors, has been successfully launched in the domestic market and has been included in the medical insurance catalog. For patients, the use of dabrafenib provides an effective drug option for the treatment of some malignancies, including melanoma. However, due to price factors, patients still have a large medication burden. According to the latest market data, the domestic price of dabrafenib in 75mg*120 tablets ranges from more than 9,000 to more than 10,000 yuan. The specific medical insurance price will vary depending on the patient's region and hospital. Patients need to consult the local hospital pharmacy.

Compared with the domestic market, the price of dabrafenib in foreign markets is different. In the Turkish market, the original research version of dabrafenib (75mg*120tablets) is priced at about 11,000 yuan, which is slightly higher than the domestic price. This difference may be related to factors such as pricing policies, taxes, and import fees in various countries. However, judging from international price comparisons, the price in the domestic market is still relatively reasonable, especially after being included in medical insurance, the patient's out-of-pocket portion will be reduced.

In order to meet the needs of more patients, the Lao Ministry of Health has approved the listing of generic versions of dabrafenib. The ingredients of this generic drug are similar to the original drug, and the efficacy is basically the same, so it has become the choice of many patients. The price of the Laotian version of dabrafenib is relatively close to the people. The price of 75mg*120 tablets is only about 2,000 yuan. The introduction of generic drugs not only provides a more economical treatment option, but also promotes market competition and is expected to reduce the price of original drugs in the future.

Outlook2025 As the drug market becomes further standardized and international competition intensifies, the price of dabrafenib may be adjusted. With the entry of more generic drugs, the downward trend in prices will become more obvious. Especially when policies are likely to gradually liberalize drug pricing, drug prices may undergo more reasonable adjustments, and patients' treatment burden is expected to be further reduced. It is expected that by 2025, the price of dabrafenib in the domestic market may decline, especially after the expansion of medical insurance coverage, the actual burden on patients will be alleviated.

Reference materials:https://go.drugbank.com/drugs/DB08912